The Food and Drug Administration (FDA) recently approved Jakafi (ruxolitinib) for treatment of chronic graft-versus-host disease (GVHD), providing another option to manage the condition, which is a common side effect in patients who have had an allogeneic transplant.
This drug has shown promising activity in chronic GVHD and we now have randomized data proving it. It is nice to have another tool available to manage these challenging cases, said Dr. Mehdi Hamadani during an interview with CURE. But in spite of this very important approval, we need to support ongoing clinical trials that are looking at other novel agents for chronic GVHD, and in fact several agents in development are looking very promising.
Hamadani, who is a professor of medicine at Medical College of Wisconsin and director of the Blood and Marrow Transplant program at Froedtert Hospital, explained that while Jakafi will not change the first-line management for patients, it provides another option for those with moderate to severe chronic GVHD who do not respond to corticosteroids.
Patients who develop chronic GVHD typically experience symptoms such as skin rash, yellow discoloration of the skin or eyes, nausea, vomiting, diarrhea or abdominal cramping. It occurs when donated blood marrow or blood stem cells from a transplant view the patients body as a foreign threat and begin to attack it.
Depending on the platform a given transplant center uses, approximately 50%-60% of patients develop chronic GVHD, Hamadani said. And arguably, I would say 30%-40% develop what we call the NIH moderate and severe chronic GVHD, that not only has impact on patients quality of life, but also is known to increase transplant-related mortality if the disease does not improve with corticosteroids, which have been the mainstay for chronic GVHD management. Historically we had limited options to manage these patients.
The data that informed Jakafis approval came from the phase 3 REACH3 trial. Researchers reported an overall response rate (ORR) or proportion of patients whose disease responded to therapy of 49.7% after 24 weeks with Jakafi compared with 25.6% with the best available therapy (BAT). On cycle seven, day one, the ORR was 70% with Jakafi and 57% with BAT.
Patients within the BAT group during the trial may have received one of at least 10 different agents, Hamadani explained.
So we are comparing an investigational agent with a variety of non-standard agents, which produces a degree of heterogeneity in the control arm. But with that limitation in mind, the observed responses in the experimental arm, that being Jakafi, at week 24 after starting treatment were twice as higher. Approximately 50% of the patients under the Jakafi arm responded compared to about a quarter of patients on the standard of care arm, so the response rates are impressive, and the durability of responses is also fairly good at six months.
Hamadani added that though they are uncommon, there are variations of GVHD that are exceedingly difficult to manage, such as when patients lungs are impacted, and they experience shortness of breath or become oxygen-dependent.
So if you look at the supplemental appendix of the publication, in lungs, there was no difference between Jakafi and best supportive care, at least in terms of response rates, and that's really a challenging form of GVHD. It's uncommon, but when it happens, it really impacts the quality of patient's life, he said.
In terms of side effects, patients receiving Jakafi most commonly experienced anemia, thrombocytopenia (low blood platelet count), infections (pathogen not specified) and viral infection.
Jakafi has a very well-known profile of toxicity because this drug has been used in patients with myelofibrosis or polycythemia vera for a number of years now, Hamadani said. We have been using Jakafi for acute GVHD, by the way, for several years now.
He added that some of the patients in his clinic who received Jakafi through expanded access programs experienced fatigue that led to a dose reduction to address the quality-of-life concern. While its important for physicians to keep track of patients side effects, they are well-managed with appropriate supportive care, and most patients are able to stay on it.
Jakafi is a very useful tool, Hamadani said. And it's extremely pleasing to see an agent that (has) become FDA-approved as well. But I think more work needs to be done to develop more active agents to prevent GVHD to begin with, and once it develops in these concerning organs, to somehow reverse it.
Additionally, he emphasized that change is needed from a systemic standpoint to address the massive copays patients often have to pay for oral anti-cancer agents, which creates a barrier for those who cannot afford it.
I can tell you a number of patients who were appropriate candidates for Jakafi in a different setting, for acute GVHD who were not able to get the drug because they couldn't afford the out-of-pocket cost copay for the drug. And I think as a nation, we need to address this problem with drug costs.
For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.
Go here to read the rest:
FDA Approval of Jakafi for Chronic GVHD Provides Another Option, But 'More Work Needs to Be Done' - Curetoday.com
- Embryonic Stem Cell Fact Sheet - University of WisconsinMadison - October 21st, 2022
- The longevity diet: Lots of beans and periodic fasts slow ageing - The New Daily - September 16th, 2022
- See-through zebrafish, new imaging method put blood stem cells in high-resolution spotlight - University of Wisconsin-Madison - August 14th, 2022
- ISCT's New Leader on the Future of Cell and Gene Therapy - The Medicine Maker - August 14th, 2022
- Erik Ranheim to become chair of Department of Pathology and Laboratory Medicine - University of Wisconsin School of Medicine and Public Health - August 5th, 2022
- It's a Holland Hat Trick: College of Health Professor Gets Three Grant Notifications in One Day - University of Utah Health Sciences - August 5th, 2022
- How long-term Covid-19 immunity paves the way for universal Covid-19 vaccines - Vox.com - August 5th, 2022
- Delayed cord blood clamping: a health boost for babies, and potentially for others - La Crosse Tribune - July 19th, 2022
- Neural stem cells: developmental mechanisms and disease modeling - June 13th, 2022
- The benefits and risks of stem cell technology - PMC - June 13th, 2022
- Hunters, Hearing Loss, and New Tech to Fix it - MeatEater - June 13th, 2022
- Cryopreservation of Hematopoietic Stem Cells - January 20th, 2022
- Post from Community: STEM Forward to honor STEM outreach and engineering excellence at the 69th annual celebration of STEM virtual event - Milwaukee... - January 20th, 2022
- Bring in the bulldozers: Cynatas CEO on how heavyweight FujiFilm will turbocharge its ... - Stockhead - January 5th, 2022
- Polymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes DelveInsight - GlobeNewswire - December 10th, 2021
- Researchers May Have Found The Gene Responsible For Cellular Aging - Anti Aging News - December 4th, 2020
- Osteoporosis treatments could be on the way after scientists identify aging gene - iNews - December 4th, 2020
- Stem Cell Assay Market In-Depth Analysis and Forecast 2017-2025 - Khabar South Asia - December 4th, 2020
- Stem Cell Assay Market In-Depth Analysis and Forecast 2017-2025 - Royal Sutton News - October 29th, 2020
- Stem Cell Assay Market to Witness Growth Acceleration During 2017-2025 - Cole of Duty - June 4th, 2020
- Clinical prospects for stem cells begin to emerge - April 28th, 2020
- Answering your sweet onion question and the science of why onions make you cry - Green Bay Press Gazette - April 28th, 2020
- New technique developed to treat hardening of internal organs - WNDU-TV - March 4th, 2020
- Scientists Grapple with US Restrictions on Fetal Tissue Research - The Scientist - March 4th, 2020
- Cells carrying Parkinson's mutation could lead to new model for studying disease - University of Wisconsin-Madison - March 4th, 2020
- Deer hunter or Bambi lover: What you should know about chronic wasting disease - Ohio's Country Journal and Ohio Ag Net - February 14th, 2020
- Cord Tissue Cell Therapy | Wisconsin Stem Cell Therapy - January 29th, 2020
- The selling of CTE: How the 'Concussion' doctor has built a career on distorted science - Stars and Stripes - January 24th, 2020
- nation briefs - Daily Herald - January 5th, 2020
- Addressing Disparities in Cancer: Factors Influencing Care, Access and Outcomes - OncoZine - December 11th, 2019
- Ausman family thankful for recoveries, support from family and community - Chippewa Herald - November 28th, 2019
- Lab: Nightmares may help the brain prepare for frightening situations in real life - Metro Newspaper UK - November 28th, 2019
- Stem Cell Assay Market Demand with Leading Key Players and New Investment Opportunities Emerge To Augment Segments in Sector By 2025 - The Denton... - November 28th, 2019
- Development of the dopaminergic system - from stem cells ... - April 15th, 2019
- Stem Cell Therapy for Back Conditions Oconomowoc, WI - January 26th, 2019
- Wisconsin Stem Cell Clinic - Forward Healthy Lifestyles - December 31st, 2018
- Knee Conditions Milwaukee, WI | Wisconsin Stem Cell Therapy - November 1st, 2018
- Stem Cells for Hip Brookfield, WI | Wisconsin Stem Cell ... - October 26th, 2018
- Geron Official Affirms iPS Cells Are the Future of Stem ... - October 13th, 2018
- Laws Governing Stem Cell Research Wisconsin Right to Life - June 23rd, 2018
- Knee Conditions | Milwaukee, WI | Wisconsin Stem Cell - October 16th, 2017
- Sponsors World Stem Cell Summit - October 15th, 2017
- Stem Cell Therapy - Cendant Cellular Therapies - Denver ... - October 15th, 2017
- Madison man is first Hmong-American to get an MD-Ph.D. - Post-Bulletin - July 10th, 2017
- Stem cells | | News | UW-Madison - November 20th, 2016
- Public Outreach | Stem Cell and Regenerative Medicine Center - November 20th, 2016
- Chapter 34: Stem Cells - The Hastings Center - September 28th, 2016
- Wisconsin Stem Cell Therapy | Stem Cell Treatments - October 10th, 2015
- 1. Embryonic Stem Cells [Stem Cell Information] - October 1st, 2015
- WISCONSIN STEM CELL SYMPOSIUM - BTC Institute - October 1st, 2015
- How Stem Cells Work - HowStuffWorks - October 1st, 2015
- Variations in cell programs control cancer and normal stem ... - September 8th, 2015
- Local students take part in stem cell camp | Local | apg ... - August 1st, 2015
- Wisconsin Roundup: VC Funding, StartUp Health, Stem Cells ... - July 2nd, 2015
- Stem cell expert: Bart Starr treatment shows need for ... - June 29th, 2015
- Study Reveals How Imaging Technology Can Track Stem Cell ... - June 11th, 2015
- Wisconsin Stem Cell Now Issues and Legislation - June 11th, 2015
- UW-Madison Heart Stem Cell Study Among American Heart ... - May 28th, 2015
- Whitehead Institute - News - 2008 - Human blood stem cells ... - May 1st, 2015
- Science meets art: 2015 Cool Science Images unveiled - April 11th, 2015
- Kentucky Fan Gets Life-Saving Stem Cell Donation From Univ. of Wisconsin Student - April 3rd, 2015
- Blood ties: Ky. basketball fan gets Wisconsin assist - April 2nd, 2015
- Wisconsin Stem Cell Roundtable (WiSCR) - Welcome to Stem ... - March 13th, 2015
- New insights into 3-D genome organization and genetic variability - March 10th, 2015
- UW Stem Cell Researchers Building a 'Retinal Patch' to ... - February 27th, 2015
- New Insights into 3D Genome Organization and Genetic Variability - February 18th, 2015
- First contracting human muscle grown in laboratory - January 14th, 2015
- Eye Researchers Awarded Grant for Stem-Cell Research in ... - January 3rd, 2015
- UW-Madison Stem Cell & Regenerative Medicine Center - December 27th, 2014
- Baby cells learn to communicate using the lsd1 gene - December 16th, 2014
- Advances in lymphoma and multiple myeloma treatment seek to improve outcomes for patients - December 9th, 2014
- Research to Prevent Blindness, Inc. and the International Retinal Research Foundation Announce Catalyst Awards for AMD ... - December 4th, 2014
- James A. Thomson - Wisconsin Stem Cell Research Program - December 1st, 2014
- Programs - Cell and Regenerative Biology, University of ... - November 18th, 2014
- Morgridge Scientists Find Way to 'Keep the Lights on' for Cell Self-Renewal - November 13th, 2014
- BioEden the specialist tooth stem cell bank announce ... - November 12th, 2014
- Survival rates in pediatric umbilical cord transplants may indicate a new standard of care - October 30th, 2014
- UW-Madison senior Maria Estevez discusses women pursuing STEM fields - October 27th, 2014
- Cashton man goes from winning state award to battling cancer - October 12th, 2014
- Career Opportunities | Stem Cell and Regenerative Medicine ... - September 26th, 2014